Physician profile
Rhys Irvine
NPI 1609192905
$850.36
in general payments reported to CMS, 2019-2025
16 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Pediatric Urology provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.14 · 2020: $85.71 · 2021: $136 · 2022: $192 · 2023: $249 · 2024: $42.63 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $124.35 | 2019-2023 | Ultomiris |
| Cmp Pharma, INC. | $88.37 | 2022-2023 | Norliqva |
| Mallinckrodt Hospital Products INC. | $88.05 | 2020-2025 | Acthar |
| Allergan, INC. | $86.61 | 2021 | |
| Mayne Pharma Commercial LLC | $84.89 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $69.20 | 2020-2022 | |
| Abbvie INC. | $65.68 | 2023 | |
| Urogen Pharma, INC. | $42.63 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $35.37 | 2020-2021 | |
| Kyowa Kirin, INC. | $34.95 | 2023-2025 | |
| Axonics, INC. | $34.12 | 2022 | |
| Genzyme Corporation | $23.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.56 | 2025 | Givlaari |
| Coloplast Corp | $19.57 | 2022 | |
| Travere Therapeutics, INC. | $16.93 | 2023 | Cholbam |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Palette Life Sciences, INC. | $13.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rhys Irvine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.